Autolus Therapeutics Ltd reported $24.57M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
AstraZeneca USD 2.52B 2.73B Jun/2026
Autolus Therapeutics Ltd USD 24.57M 762K Mar/2026
Hikma Pharmaceutical USD 959M 492.5M Dec/2025
Novartis USD 3.71B 251M Jun/2026
Roche Holding CHF 7.85B 630M Jun/2026
Silence Therapeutics USD 12K 52K Dec/2025